The earliest investigation pairing a PD‐(L)1 inhibitor with a broad‐spectrum anti‐angiogenic TKI in the first‐line setting was a phase I trial evaluating sintilimab plus anlotinib in treatment‐naïve, driver‐mutation–negative stage IIIB–IV NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.